- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02936466
Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group (Bipolife)
Bipolar disorder is a condition characterized by succession of episodes- manic, hypomanic, and depressive episodes. Major risks factors of relapses are poor compliance, sleep disorder, and toxics consumption. The aims of psychoeducation programs are to increase compliance and knowledge about bipolar disorder. Serious game are supposed, in bipolar disorder, to strengthen the efficacy of psychoeducation programs. Bipolife® is a serious game which purpose is to help bipolar patients to deal with their conditions, through 3 mains messages : to pursue the treatment, to have daily routine and to request the psychiatrist in case of relapse.
This is a multicentric randomized controlled study with two harms parallels. After a classic psychoeducation group program, patients are randomized in two groups : interventional group and control group with treatment as usual.
The main objective is to evaluate the observance in the two groups. The other objectives are to evaluate daily routine, global functioning, and access to health care. Evaluations are realized at one and four months after inclusion visit. Acceptability and satisfaction about the serious game Bipolife® will be assessed in the interventional group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bipolife® is a serious game for bipolar patients, developed by Astra Zeneca laboratory in collaboration with a french company named Ubisoft. The aim of this interactive tool is to help patient to have a better understanding of their condition and to identify their daily routine which can impact on it.
Three visits :
At the inclusion visit (V0), on the 15days following the end of the psychoeducation group, the investigator evaluate mood, habits, daily routine, and verify inclusion criteria of the participants, in particular euthymic status. The participants are randomized by bloc in each center, in two groups : interventional group (Bipolife®) and control group.
Instructions on interventional group are to periodically connect to BIPOLIFE until next visit.
On the first visit, one month later (V1) and on the second visit, four months later (V2), the investigator evaluate compliance, routine habits and mood.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- University Montpellier hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- diagnosis of bipolar disorder according to the Diagnostic and Statistical Manual (DSM) IV
- euthymic status at least since 3 months
- participation to a psychoeducation group ending on the 15 last days
- realized at less 50% of the sessions of psychoeducation group
- free access to a computer with internet connection
- signed informed consent
Exclusion criteria:
- decline of participation
- patient on protective measures (guardianship or trusteeship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interventional group
Bipolife group
|
The participant is proposed to play to the serious game Bipolife® with following instructions :
After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose "energy" and "mood" points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition. |
|
No Intervention: Control group
No specific intervention, treatment as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compliance rate
Time Frame: At 4 months after the inclusion
|
Evaluation of patient compliance by Medication Adherence Rating Scale (MARS) score.
|
At 4 months after the inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evolution of toxic consumption
Time Frame: Between 1 and 4 months after the inclusion
|
evaluation of toxic consumption : patient will be asked about his consumption, and to pass the french scale Cut-down, Annoyed, Guilty, Eye-opener (CAGE- DETA)
|
Between 1 and 4 months after the inclusion
|
|
Evolution of sleep disturbance
Time Frame: Between 1 and 4 months after the inclusion
|
evaluation of sleep disturbance (by Pittsburgh Sleep Quality Index PSQI)
|
Between 1 and 4 months after the inclusion
|
|
Evolution of the alimentation
Time Frame: Between 1 and 4 months after the inclusion
|
evaluation of alimentation (patient will be asked about his alimentation)
|
Between 1 and 4 months after the inclusion
|
|
Global functioning
Time Frame: At 1 and 4 months after the inclusion
|
evaluation of global functioning is realized by the Functioning Assessment Short Test (FAST) scale.
|
At 1 and 4 months after the inclusion
|
|
Ability to access health care in emergency description : number of emergency consultation for psychiatric reason
Time Frame: At 1 and 4 months after the inclusion
|
evaluation of the ability to require to health care structures : Patients will be asked about their consultations and hospitalisations during the follow-up
|
At 1 and 4 months after the inclusion
|
|
acceptability and satisfaction
Time Frame: At 1 and 4 months after the inclusion
|
only on the "interventional group" : evaluation of the acceptability and satisfaction by a home made acceptability scale.
|
At 1 and 4 months after the inclusion
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF 9238
- 2013-A01481-44 (Other Identifier: Agence Nationale de Sécurité des Médicaments)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.